Contrast media developer Advanced Magnetics announced in late December its submission to the FDA of a supplemental new drug application for Feridex I.V. The application seeks an expansion of indications to include differentiation of liver lesions as
Contrast media developer Advanced Magnetics announced in late December its submission to the FDA of a supplemental new drug application for Feridex I.V. The application seeks an expansion of indications to include differentiation of liver lesions as benign or metastatic. The company also hopes to change the dosing regimen to allow more rapid infusion. Expanding the labeling for Feridex I.V. could make the MRI contrast medium more competitive, according to the company. The agent, which was originally approved by the FDA on Aug. 30, 1996, is being marketed in the U.S. by Berlex Laboratories, a subsidiary of Schering of Germany.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.